Engaging healthcare teams to increase access to medications for opioid use disorder

被引:1
作者
Oberman, Rebecca S. [1 ]
Huynh, Alexis K. [1 ]
Cummings, Kelsey [1 ]
Resnick, Adam [1 ]
Taylor, Stephanie L. [1 ,2 ,3 ]
Bergman, Alicia A. [1 ]
Chang, Evelyn T. [1 ,4 ]
机构
[1] VHA Ctr Study Healthcare Innovat Implementat & Pol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA
[4] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gen Internal Med, Los Angeles, CA USA
关键词
buprenorphine; implementation science; methadone; naltrexone; opioid use disorder; quality improvement; QUALITY IMPROVEMENT; BUPRENORPHINE TREATMENT; UNITED-STATES; OVERDOSE; DEPRESSION; GUIDELINE; NALOXONE; OUTCOMES; LESSONS;
D O I
10.1111/1475-6773.14371
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ObjectiveTo assess the effectiveness of evidence-based quality improvement (EBQI) as an implementation strategy to expand the use of medications for opioid use disorder (MOUD) within nonspecialty settings.Data Sources and Study SettingWe studied eight facilities in one Veteran Health Administration (VHA) region from October 2015 to September 2022 using administrative data.Study DesignInitially a pilot, we sequentially engaged seven of eight facilities from April 2018 to September 2022 using EBQI, consisting of multilevel stakeholder engagement, technical support, practice facilitation, and data feedback. We established facility-level interdisciplinary quality improvement (QI) teams and a regional-level cross-facility collaborative. We used a nonrandomized stepped wedge design with repeated cross sections to accommodate the phased implementation. Using aggregate facility-level data from October 2015 to September 2022, we analyzed changes in patients receiving MOUD using hierarchical multiple logistic regression.Data Collection/Extraction MethodsEligible patients had an opioid use disorder (OUD) diagnosis from an outpatient or inpatient visit in the previous year. Receiving MOUD was defined as having been prescribed an opioid agonist or antagonist treatment or a visit to an opioid substitution clinic.Principal FindingsThe probability of patients with OUD receiving MOUD improved significantly over time for all eight facilities (average marginal effect [AME]: 0.0057, 95% CI: 0.0044, 0.0070) due to ongoing VHA initiatives, with the probability of receiving MOUD increasing by 0.577 percentage points, on average, each quarter, totaling 16 percentage points during the evaluation period. The seven facilities engaging in EBQI experienced, on average, an additional 5.25 percentage point increase in the probability of receiving MOUD (AME: 0.0525, 95%CI: 0.0280, 0.0769). EBQI duration was not associated with changes.ConclusionsEBQI was effective for expanding access to MOUD in nonspecialty settings, resulting in increases in patients receiving MOUD exceeding those associated with temporal trends. Additional research is needed due to recent MOUD expansion legislation.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Healthcare Expenditures Associated With Implementing an External Facilitation Program to Increase the Prescribing of Medications Used for the Treatment of Opioid Use Disorder Among Veterans
    Esmaeili, Aryan
    Hagedorn, Hildi J.
    Garcia, Carla C.
    Bangerter, Ann
    Gustavson, Allison M.
    Kenny, Marie E.
    Miller, Wendy
    Ackland, Princess E.
    Clothier, Barbara A.
    Noorbaloochi, Siamak
    Gordon, Adam J.
    Bounthavong, Mark
    SUBSTANCE USE & ADDICTION JOURNAL, 2025,
  • [42] Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use
    Noam, Krista R.
    Schmutte, Timothy J.
    Pirard, Sandrine
    Bourdon, Carol
    Langless, Daniel
    Plant, Robert
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (03) : E199 - E201
  • [43] County-level access to opioid use disorder medications in medicare Part D (2010-2015)
    Abraham, Amanda J.
    Adams, Grace Bagwell
    Bradford, Ashley C.
    Bradford, William D.
    HEALTH SERVICES RESEARCH, 2019, 54 (02) : 390 - 398
  • [44] Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review
    Chladek, Jason S.
    Chui, Michelle A.
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [45] Perceptions around medications for opioid use disorder among a diverse sample of US adults
    Jaffe, Kaitlyn
    Slat, Stephanie
    Chen, Liying
    Macleod, Colin
    Bohnert, Amy
    Lagisetty, Pooja
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 163
  • [46] The receipt of medications for opioid use disorder among pregnant individuals in the USA: a multilevel analysis
    Curran, Laura
    Manuel, Jennifer
    DRUGS HABITS AND SOCIAL POLICY, 2024, 25 (01): : 51 - 66
  • [47] Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder
    Ellis, Matthew S.
    Buttram, Mance E.
    Kasper, Zachary A.
    DRUG AND ALCOHOL DEPENDENCE, 2022, 234
  • [48] Medications for Opioid Use Disorder and Mortality and Hospitalization Among People With Opioid Use-related Infections
    Figgatt, Mary C.
    Hincapie-Castillo, Juan M.
    Schranz, Asher J.
    Dasgupta, Nabarun
    Edwards, Jessie K.
    Jackson, Bradford E.
    Marshall, Stephen W.
    Golightly, Yvonne M.
    EPIDEMIOLOGY, 2024, 35 (01) : 7 - 15
  • [49] Medication Treatment of Opioid Use Disorder
    Bell, James
    Strang, John
    BIOLOGICAL PSYCHIATRY, 2020, 87 (01) : 82 - 88
  • [50] Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care
    Evelyn T. Chang
    Rebecca S. Oberman
    Amy N. Cohen
    Stephanie L. Taylor
    Elisa Gumm
    Aram S. Mardian
    Shawn Toy
    Araceli Revote
    Britney Lewkowitz
    Elizabeth M. Yano
    Journal of General Internal Medicine, 2020, 35 : 918 - 926